CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo

Isabelle Hubeek, E. M. Comijn, C. L. Van der Wilt, R. L. Merriman, J. M. Padron, G. J.L. Kaspers, G. J. Peters

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

23 Citaten (Scopus)

Samenvatting

N-acetyl-dinaline (CI-994) is an investigational anti-cancer drug which inhibits histone deacetylases. We evaluated the interaction between CI-994 and conventional chemotherapeutics used in acute myeloid leukemia (AML) in a rat model for AML and Brown Norway rat acute myelocytic leukemia (BNML). In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism. In vivo, higher dosages of CI-994 induced complete remissions. CI-994/ ara-C was very active against BNML. The combinations of CI-994/ daunorubicin and CI-994/mitoxantrone were also active against BNML. This study demonstrates favorable in vitro and in vivo interactions between CI-994 and conventional anti-cancer agents used for the treatment of AML.

Originele taal-2Engels
Pagina's (van-tot)1517-1523
Aantal pagina's7
TijdschriftOncology Reports
Volume19
Nummer van het tijdschrift6
StatusGepubliceerd - jun. 2008
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo'. Samen vormen ze een unieke vingerafdruk.

Citeer dit